Figure 1.

Comparison of the levels of serum anti-JMJD6 antibodies (s-JMJD6-Abs) in healthy donors (HDs) and patients with chronic cerebral infarction (CCI), acute cerebral infarction (ACI), transient ischemic attack (TIA)/asymptomatic cerebral infarction (Asympt-CI), and deep and subcortical white matter hyperintensity (DSWMH). (a) The figure shows the scatter dot plot of the levels of s-JMJD6-Abs examined using amplified luminescence proximity homogeneous assay-linked immunosorbent assay (AlphaLISA). The bars represent the medians and quartiles. The p-values were calculated using the Kruskal–Wallis test (Mann–Whitney U test with Bonferroni correction applied). Table 1 summarizes the exact values. (b–e) The capacities of s-JMJD6-Abs for detecting CCI (b), ACI (c), TIA/Asympt-CI (d), and DSWMH (e) were assessed through receiver operating characteristic (ROC) curve analysis. The numbers in the figures indicate the cutoff values for marker levels, and the numbers in parentheses indicate sensitivity (left) and specificity (right). p-values, areas under the curve (AUCs), and 95% confidence intervals (95% CI) are also shown. (f–m) The associations of s-JMJD6-Ab levels with sex (f), body mass index (BMI) (g), diabetes mellitus (DM) (h), hypertension (HT) (i), cardiovascular diseases (CVDs) including acute myocardial infarction and unstable angina pectoris (j), lipidemia (k), smoking (l), and alcohol drinking (m) were examined in the Sawara Hospital cohort. The p-values were calculated using the Mann–Whitney U test, and the bars represent the medians and quartiles; “+” indicates “presence of”; “−” indicates “absence of”.